>>Ipilimumab is considered one of the most important drugs in Bristol's development pipeline.
It is also being tested in metastatic melanoma, for which there are currently few treatment options. Highly anticipated late-stage data in melanoma has been kept under wraps and will be one of the highlight presentations at the June meeting.<<
"kept under wraps" may be only one reason the class-action shareholders suits against BMY/MEDX have not yet settled. I also understand the SEC has been asked to investigate GS and its role in advising MEDX that the $16 takeover was for "fair value."
News 
Market Data 
Discover 
